CD274 and gastric neoplasm: Nivolumab plus fluoropyrimidine- and oxaliplatin-based chemotherapy is a preferred first-line treatment option for patients with HER2 negative gastric tumors with programmed cell death ligand 1(PD-L1) expression levels by combined positive score(CPS) of ≥5 (category 1) and is useful under certain circumstances for tumors with PD-L1 expression levels by CPS of <5 (2).